Restless legs syndrome/Willis Ekbom disease: evaluation and treatment (Q38217286)

31 August 2017

Restless legs syndrome/Willis Ekbom disease: evaluation and treatment (English)

1 reference

31 August 2017

1

Richard P Allen

1 reference

31 August 2017

1 April 2014

1 reference

International Review of Psychiatry

31 August 2017

1 reference

31 August 2017

26

1 reference

31 August 2017

2

1 reference

31 August 2017

248-262

1 reference

The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting.

31 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

MRI measurement of brain iron in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Comparison of pregabalin with pramipexole for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

The role of iron in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Family history study of the restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome prevalence and impact: REST general population study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Low plasma iron status and akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome: a clinical study of 55 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Bupropion and restless legs syndrome: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome augmentation associated with tramadol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Augmentation: understanding a key feature of RLS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Extracranial hypoglossal schwannoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Excessive Daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Intravenous iron dextran for severe refractory restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Pregnancy accounts for most of the gender difference in prevalence of familial RLS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Motor cortex excitability in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Changes of cortical excitability after dopaminergic treatment in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

A genetic risk factor for periodic limb movements in sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Motor system excitability in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Efficacy and safety of pramipexole in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

Augmentation of restless legs syndrome with long-term tramadol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2014.904279

10.3109/09540261.2014.904279

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24892899